RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: PERCEIVE-Outreach Disease Management Program for Long COVID

Q: Is NCT07661862 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07661862?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07661862?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called "Long COVID" or Post-Acute Sequelae of SARS-CoV-2 (PASC).

Official registry: https://clinicaltrials.gov/study/NCT07661862 · University of Tasmania · enrollment listed as 577

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are PERCEIVE-Outreach Disease Management Program. The registry lists allocation as randomized. Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection.

They plan to enroll about 577 people at 2 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID

Interventions: PERCEIVE-Outreach Disease Management Program

Primary outcome (registry wording): Changes in 6-min walk distance (6MWD) at 6 months

Who it is for (from inclusion criteria)

Ages 40 Years to any
Aged forty years or older
Impaired estimated functional capacity using DASI as proxy (defined by age-normative metabolic equivalent of tasks \[METs\])
History of COVID-19 (stratified by hospital admission)
Currently symptomatic with fatigue, dyspnoea or chest pain symptoms
Medicare eligibility

Who the registry excludes

Participating in another research trial where randomly assigned treatment would be unacceptable
Mobility impairment that would impact participants' ability to perform exercise
History of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Known valvular stenosis or regurgitation of \>moderate severity, history of previous heart failure (baseline New York Heart Association \[NYHA\] \>2)
Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial

Public study contact (from the registry)

Quan Huynh, PhD

+61 03 8532 1833

quan.huynh@utas.edu.au; quan.huynh@baker.edu.au

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

2 listed

Menzies Insititute for Medical Research — Hobart, Tasmania, Australia (recruiting)
Baker Heart and Diabetes Institute — Melbourne, Victoria, Australia (not_yet_recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07661862 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07661862?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07661862?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary